N
Nang Kuang Pharmaceutical Co Ltd
TWSE:1752
Nang Kuang Pharmaceutical Co Ltd
TWSE:1752
Price:
37
TWD
0.95%
Market Closed
Market Cap:
NT$3.7B
Income Statement
Earnings Waterfall
Nang Kuang Pharmaceutical Co Ltd
Nang Kuang Pharmaceutical Co Ltd
Income Statement
Nang Kuang Pharmaceutical Co Ltd
Nang Kuang Pharmaceutical Co Ltd
Currency: TWD
| Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||
| Interest Expense |
4
|
4
|
4
|
4
|
4
|
4
|
5
|
5
|
6
|
1
|
6
|
6
|
8
|
8
|
|
| Revenue |
1 718
N/A
|
1 758
+2%
|
1 780
+1%
|
1 733
-3%
|
1 763
+2%
|
1 789
+1%
|
1 940
+8%
|
2 138
+10%
|
2 189
+2%
|
580
-74%
|
2 200
+279%
|
1 739
-21%
|
2 280
+31%
|
2 224
-2%
|
|
| Gross Profit | |||||||||||||||
| Cost of Revenue |
(1 150)
|
(1 175)
|
(1 186)
|
(1 159)
|
(1 157)
|
(1 164)
|
(1 246)
|
(1 359)
|
(1 403)
|
(383)
|
(1 452)
|
(1 102)
|
(1 443)
|
(1 416)
|
|
| Gross Profit |
568
N/A
|
583
+3%
|
594
+2%
|
574
-3%
|
606
+6%
|
625
+3%
|
695
+11%
|
778
+12%
|
786
+1%
|
197
-75%
|
748
+280%
|
636
-15%
|
837
+32%
|
808
-3%
|
|
| Operating Income | |||||||||||||||
| Operating Expenses |
(351)
|
(347)
|
(333)
|
(340)
|
(344)
|
(355)
|
(373)
|
(388)
|
(403)
|
(111)
|
(438)
|
(345)
|
(468)
|
(474)
|
|
| Selling, General & Administrative |
(205)
|
(203)
|
(199)
|
(202)
|
(203)
|
(212)
|
(229)
|
(241)
|
(253)
|
(68)
|
(267)
|
(212)
|
(285)
|
(292)
|
|
| Research & Development |
(145)
|
(142)
|
(133)
|
(136)
|
(140)
|
(142)
|
(143)
|
(146)
|
(148)
|
(42)
|
(169)
|
(130)
|
(179)
|
0
|
|
| Depreciation & Amortization |
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(2)
|
(1)
|
(2)
|
(2)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
(180)
|
|
| Operating Income |
216
N/A
|
237
+9%
|
261
+10%
|
234
-10%
|
262
+12%
|
270
+3%
|
322
+19%
|
390
+21%
|
383
-2%
|
86
-78%
|
310
+260%
|
292
-6%
|
370
+27%
|
335
-9%
|
|
| Pre-Tax Income | |||||||||||||||
| Interest Income Expense |
(13)
|
(13)
|
(12)
|
7
|
4
|
26
|
80
|
77
|
94
|
(11)
|
(17)
|
(32)
|
(48)
|
0
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
6
|
0
|
0
|
(4)
|
(4)
|
0
|
|
| Total Other Income |
10
|
10
|
(14)
|
(13)
|
(15)
|
(12)
|
9
|
9
|
12
|
1
|
10
|
5
|
9
|
(28)
|
|
| Pre-Tax Income |
213
N/A
|
233
+9%
|
235
+1%
|
229
-3%
|
251
+10%
|
284
+13%
|
411
+45%
|
476
+16%
|
495
+4%
|
76
-85%
|
303
+299%
|
261
-14%
|
326
+25%
|
307
-6%
|
|
| Net Income | |||||||||||||||
| Tax Provision |
(37)
|
(41)
|
(39)
|
(36)
|
(38)
|
(42)
|
(59)
|
(71)
|
(72)
|
(18)
|
(60)
|
(45)
|
(58)
|
(50)
|
|
| Income from Continuing Operations |
176
|
192
|
196
|
192
|
213
|
242
|
352
|
405
|
423
|
58
|
243
|
216
|
268
|
257
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
176
N/A
|
192
+9%
|
196
+2%
|
192
-2%
|
213
+11%
|
242
+14%
|
352
+46%
|
405
+15%
|
423
+4%
|
58
-86%
|
243
+319%
|
216
-11%
|
268
+24%
|
257
-4%
|
|
| EPS (Diluted) |
1.74
N/A
|
1.9
+9%
|
1.94
+2%
|
1.9
-2%
|
2.1
+11%
|
2.39
+14%
|
3.48
+46%
|
3.99
+15%
|
4.17
+5%
|
0.58
-86%
|
2.4
+314%
|
2.14
-11%
|
2.65
+24%
|
2.53
-5%
|
|
Switch to:
Switch to:
See Also
Discover More
